Q-TWiST analysis of pembrolizumab combined with chemotherapy as first-line treatment of metastatic TNBC that expresses PD-L1

被引：0
|
作者：
Fasching, P. A. [1 ]
Huang, M. [2 ]
Haiderali, A. [3 ]
Pan, W. [4 ]
Hu, P. [2 ]
Chaudhuri, M. [5 ]
De Tilleghem, C. Le Bailly [6 ]
Cappoen, N. [6 ]
O'Shaughnessy, J. [7 ]
机构：
[1] Univ Hosp Erlangen, Dept Gynecol & Obstet, Comprehens Canc Ctr Erlangen EMN, Erlangen, Germany
[2] Merck & Co Inc, Econ & Data Sci, MRL Labs, Upper Gwynedd Campus, N Wales, PA USA
[3] Merck & Co Inc, Ctr Observat & Real World Evidence, Corp Headquarters, Kenilworth, NJ USA
[4] Merck & Co Inc, Oncol Dept, Rahway, NJ 07065 USA
[5] CHEORS Complete Hlth Econ Outcomes & Res Solut, Oncol, N Wales, PA USA
[6] HTA Stat Europe MSD, Brussels, Belgium
[7] Baylor Univ, Med Ctr, Texas Oncol, Med Oncol,US Oncol, Dallas, TX USA
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷
关键词：
D O I：
10.1016/j.annonc.2022.03.177
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
159P
引用
收藏
页码：S192 / S193
页数：2
相关论文
共 50 条
  • [31] KEYNOTE-042 China Study: First-Line Pembrolizumab vs Chemotherapy in Chinese Patients with Advanced NSCLC with PD-L1 TPS ≥1%
    Wu, Y.
    Zhang, L.
    Fan, Y.
    Zhou, J.
    Zhang, L.
    Zhou, Q.
    Li, W.
    Hu, C.
    Chen, G.
    Zhang, X.
    Zhou, C.
    Dang, T.
    Penrod, J.
    Kush, D.
    Qin, Y.
    Li, B.
    Mok, T.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S290 - S291
  • [32] Cemiplimab, a Human PD-1 Monoclonal Antibody, Versus Chemotherapy in First-Line Treatment of Advanced NSCLC with PD-L1 ≥50%
    Sezer, A.
    Gogishvili, M.
    Bentsion, D.
    Kilickap, S.
    Lowczak, A.
    Gumus, M.
    Gladkov, O.
    Clingan, P.
    Sriuranpong, V.
    Rizvi, N.
    Lee, S.
    Li, S.
    Snodgrass, P.
    Navarro, M.
    Lowy, I.
    Rietschel, P.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S638 - S638
  • [33] Clinicopathologic correlates of first-line pembrolizumab effectiveness in patients with advanced NSCLC and a PD-L1 expression of ≥ 50%
    Alessio Cortellini
    Marcello Tiseo
    Giuseppe L. Banna
    Federico Cappuzzo
    Joachim G. J. V. Aerts
    Fausto Barbieri
    Raffaele Giusti
    Emilio Bria
    Diego Cortinovis
    Francesco Grossi
    Maria R. Migliorino
    Domenico Galetta
    Francesco Passiglia
    Daniele Santini
    Rossana Berardi
    Alessandro Morabito
    Carlo Genova
    Francesca Mazzoni
    Vincenzo Di Noia
    Diego Signorelli
    Alessandro Tuzi
    Alain Gelibter
    Paolo Marchetti
    Marianna Macerelli
    Francesca Rastelli
    Rita Chiari
    Danilo Rocco
    Stefania Gori
    Michele De Tursi
    Giovanni Mansueto
    Federica Zoratto
    Matteo Santoni
    Marianna Tudini
    Erika Rijavec
    Marco Filetti
    Annamaria Catino
    Pamela Pizzutilo
    Luca Sala
    Fabrizio Citarella
    Russano Marco
    Mariangela Torniai
    Luca Cantini
    Giada Targato
    Vincenzo Sforza
    Olga Nigro
    Miriam G. Ferrara
    Ettore D’Argento
    Sebastiano Buti
    Paola Bordi
    Lorenzo Antonuzzo
    Cancer Immunology, Immunotherapy, 2020, 69 : 2209 - 2221
  • [34] Cost-Effectiveness Analysis of Pembrolizumab Plus Chemotherapy vs. Chemotherapy Alone as First-Line Treatment in Patients With Esophageal Squamous Cell Carcinoma and PD-L1 CPS of 10 or More
    Zheng, Zhiwei
    Lin, Jingrong
    Zhu, Huide
    Cai, Hongfu
    FRONTIERS IN PUBLIC HEALTH, 2022, 10
  • [35] Cost-effectiveness analysis of first-line pembrolizumab treatment for PD-L1 positive, non-small cell lung cancer in China
    Liao, Weiting
    Huang, Jiaxing
    Hutton, David
    Li, Qiu
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (04) : 344 - 349
  • [36] The efficacy and safety of anti-PD-1/PD-L1 antibodies combined with chemotherapy or CTLA4 antibody as a first-line treatment for advanced lung cancer
    Xu, Xiaoling
    Huang, Zhiyu
    Zheng, Lei
    Fan, Yun
    INTERNATIONAL JOURNAL OF CANCER, 2018, 142 (11) : 2344 - 2354
  • [37] Good Response of Advanced Thymic Carcinoma with Low PD-L1 Expression to Chemotherapy plus Pembrolizumab as First-Line Therapy and to Pembrolizumab as Maintenance Therapy: A Case Report
    Nishii, Yoichi
    Furuhashi, Kazuki
    Ito, Kentaro
    Sakaguchi, Tadashi
    Suzuki, Yuta
    Fujiwara, Kentaro
    Yasuma, Taro
    Kobayashi, Tetsu
    D'Alessandro-Gabazza, Corina N.
    Gabazza, Esteban C.
    Taguchi, Osamu
    Hataji, Osamu
    PHARMACEUTICALS, 2022, 15 (07)
  • [38] Q-TWiST Analysis to Assess Benefit-Risk of Pembrolizumab in Patients with PD-L1-Positive Advanced or Metastatic Non-small Cell Lung Cancer
    Huang, Min
    Pietanza, M. Catherine
    Samkari, Ayman
    Pellissier, James
    Burke, Thomas
    Chandwani, Sheenu
    Kong, Fansen
    Pickard, A. Simon
    PHARMACOECONOMICS, 2019, 37 (01) : 105 - 116
  • [39] Pembrolizumab as first-line treatment in NSCLC with PD-L1 ≥50%: Real life results from an all-comer population
    Frost, N.
    Kollmeier, J.
    Pultermann, D.
    Tessmer, A.
    Schmittel, A.
    Schmidt, B.
    Grah, C.
    de Wit, M.
    Misch, D.
    Blum, T.
    Suttorp, N.
    Grohe, C.
    ANNALS OF ONCOLOGY, 2019, 30
  • [40] Current status of first-line treatment with pembrolizumab for non-small-cell lung cancer with high PD-L1 expression
    Ikezawa, Yasuyuki
    Mizugaki, Hidenori
    Morita, Ryo
    Tateishi, Kazunari
    Yokoo, Keiki
    Sumi, Toshiyuki
    Kikuchi, Hajime
    Kitamura, Yasuo
    Nakamura, Atsushi
    Kobayashi, Maki
    Aso, Mari
    Kimura, Nozomu
    Yoshiike, Fumiaki
    Furuta, Megumi
    Tanaka, Hisashi
    Sekikawa, Motoki
    Hachiya, Tsutomu
    Nakamura, Keiichi
    Shimokawa, Mototsugu
    Oizumi, Satoshi
    CANCER SCIENCE, 2022, 113 (06) : 2109 - 2117
12345